Drug-resistant tuberculosis: Past, present, future

Respirology

Volumn 15, Issue 3, 2010, Pages 413-432

  Chiang, Chen Yuan ^a   Centis, Rosella ^b   Migliori, Giovanni Battista ^b  

^a INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^b IRCCS   (Italy)

Author keywords

Extensively drug resistant tuberculosis; Human immunodeficiency virus; Multi drug resistant tuberculosis; Review; Risk factor

Indexed keywords

QUINOLINE DERIVED ANTIINFECTIVE AGENT;

CLINICAL FEATURE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG RESECTION; MULTIDRUG RESISTANT TUBERCULOSIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TREATMENT OUTCOME;

ANIMALS; ANTITUBERCULAR AGENTS; BIOMEDICAL RESEARCH; DRUG RESISTANCE, MICROBIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 77950214679     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2010.01738.x     Document Type: Review

References (145)

1. Crofton J. Chemotherapy of pulmonary tuberculosis. BMJ 1959 1 : 1610 1614.
2. Bai K-J, Yu M-C, Chiang C-Y et al. Short-course chemotherapy for isoniazid-resistant pulmonary tuberculosis. J. Formos. Med. Assoc. 1998 97 : 278 282.
3. Espinal MA, Kim SJ, Suarez PG et al. Standard short-course chemotherapy for drug-resistant tuberculosis. Treatment outcomes in 6 countries. JAMA 2000 283 : 2537 2545.
4. Chiang C-Y, Enarson DA, Yu M-C et al. Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study. Eur. Respir. J. 2006 28 : 980 985.
5. Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs - worldwide, 2000-2004. MMWR Morb. Mortal. Wkly. Rep. 2006 55 : 301 305.
6. Holtz TH, Cegielski JP. Origin of the term XDR-TB. Eur. Respir. J. 2007 30 : 396.
7. Migliori GB, Loddenkemper R, Blasi F et al. 125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is 'science' enough to tackle the epidemic? Eur. Respir. J. 2007 29 : 423 427.
8. Caminero JA. Extensively drug-resistant tuberculosis: is its definition correct? Eur. Respir. J. 2008 32 : 1413 1415.
9. Chiang C-Y. Outcome of extensively drug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 2009 13 : 794.
10. Migliori GB, Besozzi G, Girardi E et al. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur. Respir. J. 2007 30 : 623 626.
11. Dye C, Espinal MA. Will tuberculosis become resistant to all antibiotics? Proc. R. Soc. Lond., B, Biol. Sci. 2001 268 : 45 52.
12. Blower S, Supervie V. Predicting the future of XDR tuberculosis. (Reflection and reaction). Lancet Infect. Dis. 2007 7 : 443.
13. Dye C. Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis. Nat. Rev. 2009 7 : 81 7.
14. Cohen T, Dye C, Colijin C et al. Mathematical models of the epidemiology and control of drug-resistant TB. Expert Rev. Respir. Med. 2009 3 : 67 79.
15. David HL. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl. Microbiol. 1970 20 : 810 814.
16. Mitchison DA. Problems of drug resistance. Br. Med. Bull. 1954 10 : 115 124.
17. Crofton J, Mitchison DA. Streptomycin resistance in pulmonary tuberculosis. BMJ 1948 2 : 1009 1015.
18. British Medical Research Council. Streptomycin treatment of pulmonary tuberculosis. A Medical Research Council investigation. BMJ 1948 2 : 769 783.
19. Fox W, Sutherland I. A five-year assessment of patients in a controlled trial of streptomycin, para-aminosalicylic acid, and streptomycin plus para-aminosalicylic acid, in pulmonary tuberculosis. Report to the Tuberculosis Chemotherapy Trials Committee of the Medical Research Council. Q. J. Med. New Ser. 1956 25 : 221 243.
20. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications. Int. J. Tuberc. Lung Dis. 1999 3 (Suppl. 2 S231 79.
21. Devasia RA, Blackman A, Gebretsadik T et al. Fluoroquinolone resistance in Mycobacterium tuberculosis. The effect of duration and timing of fluoroquinolone exposure. Am. J. Respir. Crit. Care Med. 2009 180 : 365 370.
22. Wang JY, Hsueh PR, Jan IS et al. Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax 2006 61 : 903 908.
23. Long R, Chong H, Hoeppner V et al. Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone-resistant tuberculosis. Clin. Infect. Dis. 2009 48 : 1354 1360.
24. Grimaldo ER, Tupasi TE, Rivera AB et al. Increased resistance to ciprofloxacin and ofloxacin in multidrug-resistant Mycobacterium tuberculosis isolates from patients seen at a tertiary hospital in the Philippines. Int. J. Tuberc. Lung Dis. 2001 5 : 546 550.
25. Agrawal D, Udwadia ZF, Rodriguez C et al. Increasing incidence of fluoroquinolone-resistant Mycobacterium tuberculosis in Mumbai, India. Int. J. Tuberc. Lung Dis. 2009 13 : 79 83.
26. Ait-Khaled N, Alarcon E, Bissell K et al. Isoniazid preventive therapy for people living with HIV: public health challenges and implementation issues. Int. J. Tuberc. Lung Dis. 2009 13 : 927 935.
27. Cattamanchi A, Dantes RB, Metcalfe JZ et al. Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis. Clin. Infect. Dis. 2009 48 : 179 185.
28. Mitchison DA. How drug resistance emerges as a result of poor compliance during short course chemotherapy of tuberculosis. Int. J. Tuberc. Lung Dis. 1998 2 : 10 15.
29. Mitchison DA. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 1985 66 : 219 225.
30. Yoshiyama T, Yanai H, Rhiengtong D et al. Development of acquired drug resistance in recurrent tuberculosis patients with various previous treatment outcomes. Int. J. Tuberc. Lung Dis. 2004 8 : 31 8.
31. World Health Organization. The WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance. Anti-tuberculosis drug resistance in the world. Report No. 3. World Health Organization Document 2004 WHO/CDS/TB/2004.343:1-129.
32. Lutfey M, Della-Latta P, Kapur V et al. Independent origin of mono-rifampin-resistant Mycobacterium tuberculosis in patients with AIDS. Am. J. Respir. Crit. Care Med. 1996 153 : 837 840.
33. Ridzon R, Whitney CG, McKenna MT et al. Risk factors for rifampin mono-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 1998 157 : 1881 1884.
34. Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 2009 13 : 1320 1330.
35. Kleeberg HH, Boshoff MS. A World Atlas of Initial Drug Resistance. Prepared for the Scientific Committee on Bacteriology and Immunology of the International Union Against Tuberculosis. Tuberculosis Research Institute of the South African Medical Research Council, Pretoria, 1980 1 23.
36. Cohn DL, Bustreo F, Raviglione MC. Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD global surveillance project. Clin. Infect. Dis. 1997 24 (Suppl. 1 S121 30.
37. World Health Organization. Guidelines for surveillance of drug resistance in tuberculosis. World Health Organization Document 1994 WHO/TB/94.178:1-24.
38. World Health Organization. Guidelines for the surveillance of drug resistance in tuberculosis. Fourth edition. World Health Organization Document 2009 WHO/HTM/TB/2009.442.
39. World Health Organization. Anti-tuberculosis drug resistance in the world. The WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance. World Health Organization Document 1997 WHO/TB/97.229:1-227.
40. World Health Organization. The WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance. Anti-tuberculosis drug resistance in the world. Report No. 2 - prevalence and trends. World Health Organization Document 2000 WHO/CDC/TB/2000.278:1-253.
41. World Health Organization. The WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance. Anti-tuberculosis drug resistance in the world. Report No. 4. World Health Organization Document 2008 WHO/HTM/TB/2008.394:1-120.
42. Van Deun A, Salim AH, Daru P et al. Drug resistance monitoring: combined rates may be the best indicator of programme performance. Int. J. Tuberc. Lung Dis. 2004 8 : 23 30.
43. Laszlo A, Rahman M, Espinal M et al. Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD Supranational Reference Laboratory Network: five rounds of proficiency testing, 1994-1998. Int. J. Tuberc. Lung Dis. 2002 6 : 748 756.
44. Migliori GB, Lange C, Centi R et al. Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. Eur. Respir. J. 2008 31 : 1155 1159.
45. Migliori GB, Lange C, Girardi E et al. Extensively drug-resistant tuberculosis is worse than multidrug-resistant tuberculosis: different methodology and settings, same results. Clin. Infect. Dis. 2008 46 : 958 959.
46. Migliori GB, Lange C, Girardi E et al. Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis? Eur. Respir. J. 2008 31 : 904 910.
47. Migliori GB, Sotgiu G, D'Arcy Richardson M et al. Consensus not yet reached on key drugs for extensively drug-resistant tuberculosis treatment. Clin. Infect. Dis. 2009 49 : 315 316.
48. Wright A, Zignol M, Van Deun A et al. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 2009 373 : 1861 1873.
49. World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO Report 2009. World Health Organization Document 2009 WHO/HTM/TM/2009.411:1-303.
50. Vernon A, Burman W, Benator D et al. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Lancet 1999 353 : 1843 1847.
51. Zignol M, Hosseini MS, Wright A et al. Global incidence of multidrug-resistant tuberculosis. J. Infect. Dis. 2006 194 : 479 485.
52. Blower SM, Chou T. Modeling the emergence if the 'hot zones': tuberculosis and the amplification dynamics of drug resistance. Nat. Med. 2004 10 : 1111 1116.
53. Cohen T, Coljin C, Wright A et al. Challenges in estimating the total burden of drug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 2008 177 : 1302 1306.
54. Sotgiu G, Ferrara G, Matteelli A et al. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur. Respir. J. 2009 33 : 871 881.
55. Kim DH, Kim HJ, Park SK et al. Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 2008 178 : 1075 1082.
56. Migliori GB, Cirillo DM, Spanevello A et al. Ripped from the headlines: how can we harness communications to control TB? Eur. Respir. J. 2007 30 : 194 198.
57. Quy HTW, Lan NTN, Borgdorff MW et al. Drug resistance among failure and relapse cases of tuberculosis: is the standard re-treatment regimen adequate? Int. J. Tuberc. Lung Dis. 2003 7 : 631 636.
58. Migliori GB, Espinal M, Danilova ID et al. Frequency of recurrence among MDR-TB cases 'successfully' treated with standardised short-course chemotherapy. Int. J. Tuberc. Lung Dis. 2002 6 : 858 864.
59. Migliori GB, D'Arcy Richardson M, Lange C. Of blind men and elephants: making sense of extensively drug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 2008 178 : 1000 1001.
60. World Health Organization. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. World Health Organization Document 2008 WHO/HTM/TB/2008.392:1-20.
61. Trebucq A, Anagonou S, Gninafon M et al. Prevalence of primary and acquired resistance of Mycobacterium tuberculosis to antituberculosis drugs in Benin after 12 years of short-course chemotherapy. Int. J. Tuberc. Lung Dis. 1999 3 : 466 470.
62. Espinal MA, Laserson K, Camacho M et al. Determinants of drug-resistant tuberculosis: analysis of 11 countries. Int. J. Tuberc. Lung Dis. 2001 5 : 887 893.
63. Chiang CY, Hsu CJ, Huang RM et al. Antituberculosis drug resistance among retreatment tuberculosis patients in a referral center in Taipei. J. Formos. Med. Assoc. 2004 103 : 411 415.
64. Saravia JC, Appleton SC, Rich ML et al. Retreatment strategies when first-line tuberculosis therapy fails. Int. J. Tuberc. Lung Dis. 2005 9 : 421 429.
65. Becerra MC, Freeman J, Bayona J et al. Using treatment failure under effective directly observed short-course chemotherapy programs to identify persons with multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 2000 4 : 108 114.
66. Law WS, Yew WW, Chiu Leung C et al. Risk factors for multidrug-resistant tuberculosis in Hong Kong. Int. J. Tuberc. Lung Dis. 2008 12 : 1065 1070.
67. Faustini A, Hall AJ, Perucci CA. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax 2006 61 : 158 163.
68. Frieden TR, Sterling T, Pablos-Mendez A et al. The emergence of drug-resistant tuberculosis in New York City. N. Engl. J. Med. 1993 328 : 521 526.
69. Kliiman K, Altraja A. Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB. Eur. Respir. J. 2009 33 : 1085 1094.
70. Casal M, Vaquero M, Rinder H et al. A case-control study for multidrug-resistant tuberculosis: risk factors in four European countries. Microb. Drug Resist. 2005 11 : 62 7.
71. Clark CM, Li J, Driver CR et al. Risk factors for drug-resistant tuberculosis among non-US-born persons in New York City. Int. J. Tuberc. Lung Dis. 2005 9 : 964 969.
72. Jakubowiak WM, Bogorodskaya EM, Borisov ES et al. Risk factors associated with default among new pulmonary TB patients and social support in six Russian regions. Int. J. Tuberc. Lung Dis. 2007 11 : 46 53.
73. Ruddy M, Balababanova Y, Graham C et al. Rates of drug resistance and risk factor analysis in cilvilian and prison patients with tuberculosis in Samara Region, Russia. Thorax 2005 60 : 130 135.
74. Suchindran S, Brouwer ES, Van Rie A. Is HIV infection a risk factor for multi-drug resistant tuberculosis? A systematic review. PLoS ONE 2009 4 (5 e5561 doi:10.1371/journal.pone.0005561.
75. Coker R, McKee M, Atun R et al. Risk factors for pulmonary tuberculosis in Russia: case-control study. BMJ 2006 332 : 85 7.
76. Balabanova Y, Ruddy M, Hubb J et al. Multidrug-resistant tuberculosis in Russia: clinical characteristics, analysis of second-line drug resistance and development of standardized therapy. Eur. J. Clin. Microbiol. Infect. Dis. 2005 24 : 136 139.
77. Espinal MA. Time to abandon the standard retreatment regimen with first-line drugs for failures of standard treatment. Int. J. Tuberc. Lung Dis. 2003 7 : 607 608.
78. Caminero JA. Likelihood of generating MDR-TB and XDR-TB under adequate National Tuberculosis Programme implementation. Int. J. Tuberc. Lung Dis. 2008 12 : 869 877.
79. Migliori GB, Richardson MDA, Sotgiu G et al. MDR - and XDR-TB in the West: Europe and USA: epidemiology, surveillance and control. Clin. Chest Med. 2009 30 : 637 665.
80. Caminero JA. Treatment of multidrug-resistant tuberculosis: evidence and controversies. Int. J. Tuberc. Lung Dis. 2006 10 : 829 837.
81. Migliori GB, Eker B, Richardson MD et al. A retrospectve TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur. Respir. J. 2009 34 : 387 393.
82. Koh WJ, Kwon OJ, Gwak H et al. J. Antimicrob. Chemother. 2009 64 : 388 391.
83. Hugonnet JE, Tremblay LW, Boshoff HIE. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 2009 323 : 1215 1218.
84. Chan ED, Laurel V, Strand MJ et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 2004 169 : 1103 1109.
85. Goble M, Iseman MD, Madsen LA et al. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N. Engl. J. Med. 1993 328 : 527 532.
86. Park SK, Kim CT, Song SD. Outcome of chemotherapy in 107 patients with pulmonary tuberculosis resistant to isoniazid and rifampicin. Int. J. Tuberc. Lung Dis. 1998 2 : 877 884.
87. Flament-Saillour M, Robert J, Jarlier V et al. Outcome of multi-drug-resistant tuberculosis in France. A nationwide case-control study. Am. J. Respir. Crit. Care Med. 1999 160 : 587 593.
88. Kim HJ, Hong YP, Kim SJ et al. Ambulatory treatment of multidrug-resistant pulmonary tuberculosis patients at a chest clinic. Int. J. Tuberc. Lung Dis. 2001 5 : 1129 1136.
89. Laserson KF, Thorpe LE, Leimane V et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 2005 9 : 640 645.
90. Chiang C-Y, Caminero JA, Enarson DA. Reporting on multidrug-resistant tuberculosis: a proposed definition for the treatment outcome 'failed'. Int. J. Tuberc. Lung Dis. 2009 13 : 548 550.
91. Orenstein EW, Basu S, Shah NS et al. Treatment outcome among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect. Dis. 2009 9 : 153 161.
92. Nathanson E, Lambregts van Weezenbeek C, Rich ML et al. Multidrug-resistant tuberculosis management in resource-limited settings. Emerg Infect. Dis. 2006 12 : 1389 1397.
93. Gandhi NR, Moll A, Sturm AW et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis in a rural area of South Africa. Lancet 2006 368 : 1575 1580.
94. Shean K, Badri M, Page-Shipp L et al. South African patients with extensively drug-resistant tuberculosis have poor outcomes regardless of HIV status. Eur. Respir. J. 2009 34 (Suppl. 53 Abstract N 5068.
95. Torun T, Tahaoglu K, Ozmen I et al. The role of surgery and fluoroquinolones in the treatment of multidrug-reistant tuberculosis. Int. J. Tuberc. Lung Dis. 2007 11 : 979 985.
96. Chiang C-Y, Yu M-C, Bai K-J et al. Pulmonary resection in the treatment of patients with pulmonary multidrug-resistant tuberculosis in Taiwan. Int. J. Tuberc. Lung Dis. 2001 5 : 272 277.
97. Somocurcio JG, Sotomayor A, Shin S et al. Surgery for patients with drug-resistant tuberculosis: report of 121 cases receiving community-based treatment in Lima, Peru. Thorax 2007 62 : 416 421.
98. Dravniece G, Cain KP, Holtz TH et al. Adjunctive resectional lung surgery for extensively drug-resistant tuberculosis. Eur. Respir. J. 2009 34 : 180 183.
99. Iseman MD, Madsen L, Goble M et al. Surgical intervention in the treatment of pulmonary disease caused by drug-resistant Mycobacterium tuberculosis. Am. Rev. Respir. Dis. 1990 141 : 623 625.
100. Motus IY, Skorniakov SN, Sokolov VA et al. Reviving an old idea: can artificial pneumothorax play a role in the modern management of tuberculosis? Int. J. Tuberc. Lung Dis. 2006 10 : 571 577.
101. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. World Health Organization Document 2008 WHO/HTM/TB/2008.402:1-247.
102. Kim SJ. Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur. Respir. J. 2005 25 : 564 569.
103. Kim SJ, Espinal MA, Abe C et al. Is second-line anti-tuberculosis drug susceptibility testing reliable? (Correspondence). Int. J. Tuberc. Lung Dis. 2004 8 : 1157 1158.
104. Yew WW, Chan CK, Chau CH et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin- containing regimens. Chest 2000 117 : 744 751.
105. Perez-Guzman C, Vargaz MH, Martinez-Rossier LA et al. Results of a 12-month regimen for drug-resistant pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 2002 6 : 1102 1109.
106. Diacon AH, Pym A, Grobusch M et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N. Engl. J. Med. 2009 360 : 2397 2405.
107. Wells CD, Cegielski JP, Nelson LJ et al. HIV infection and multidrug-resistant tuberculosis - the perfect storm. J. Infect. Dis. 2007 196 (Suppl S86 107.
108. World Health Organization. WHO policy on TB infection control in health-care facilities, congregate settings and households. World Health Organization Document 2009 WHO/HTM/TB/2009.419:1-40.
109. Escombe AR, Oeser CC, Gilman RH et al. Natural ventilation for the prevention of airborne contagion. PLoS Med. 2007 4 : e68 doi:10.1371/journal. pmed.0040068.
110. Harries AD, Hargreaves NJ, Gausi F et al. Preventing tuberculosis among health workers in Malawi. Bull. World Health Organ. 2002 80 : 526 531.
111. World Health Organization. Guidelines for the prevention of tuberculosis in health care facilities in resource-limited settings. World Health Organization Document 1999 WHO/CDC/TB/99.269:1-51.
112. Chiang C-Y, Enarson DA, Fujiwara PI et al. Strategies of extensively drug-resistant TB risk management for health workers and other care givers. Expert Rev. Respir. Med. 2008 2 : 47 54.
113. Coyne KM, Pozniak AL, Lamorde M et al. Pharmacology of sceond-line antituberculosis drugs and potential for interactions with antiretroviral agents. AIDS 2009 23 : 437 446.
114. Middlebrook G, Cohn ML. Some observations on the pathogenicity of isoniazid-resistant variants of tubercle bacilli. Science 1953 118 : 297 299.
115. Ordway DJ, Sonnenberg MG, Donahue SA et al. Drug-resistant strains of Mycobacterium tuberculosis exhibit a range of virulence for mice. Infect. Immun. 1995 63 : 741 743.
116. van Soolingen D, de Haas PEW, van Doorn HR et al. Mutations at amino acid position 315 of the katG gene are associated with high-level resistance to isoniazid, other drug resistance, and successful transmission of Mycobacterium tuberculosis in The Netherlands. J. Infect. Dis. 2000 182 : 1788 1790.
117. Ano H, Matsumoto T, Suetake T et al. Relationship between the isoniazid-resistant mutation katGS315T and the prevalence of MDR-/XDR-TB in Osaka, Japan. Int. J. Tuberc. Lung Dis. 2008 12 : 1300 1305.
118. Gagneux S, Davis Long C, Small PM et al. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 2006 312 : 1944 1946.
119. Cohen T, Murray M. Modeling epidemics of multidrug-resistant M. tuberculosis of heterogenous fitness. Nat. Med. 2004 10 : 1117 1121.
120. World Health Organization. Control of XDR-TB - Update on progress since the Global XDR-TB Task Force Meeting, 9-10 October 2006 Accessed 12 February 2010.] Available at http://www.who.int/tb/challenges/xdr/globaltaskforce-update- feb07.pdf
121. World Health Organization, Stop TB Partnership. The Stop TB Strategy. World Health Organization Document 2006 WHO/HTM/2006.37:1-20.
122. World Health Organization. The global MDR-TB & XDR-TB response plan 2007-2008. World Health Organization Document 2007 WHO/HTM/STB/2007.387:1-51.
123. The global tuberculosis control and patient care. The Beijing "call for action" on tuberculosis control and patient care: together addressing the global M/XDR-TB epidemic Accessed 12 February 2010.] Available from URL: http://www.who.int/tb-beijingmeeting/media/en-call-for-action.pdf
124. Matteelli A, Migliori GB, Cirillo D et al. Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis: epidemiology and control. Expert Rev. Anti Infect. Ther. 2007 5 (5 857 871.
125. Cobelens FGJ, Heldal E, Kimerling ME et al. Scaling up programmatic managment of drug-resistant tuberculosis: aprioritized research agenda. PLoS Med. 2008 5 (7 e150 doi:10.1371/journal.pmed.0050150.
126. Chiang C-Y. State of the art series on drug-resistant tuberculosis: it's time to protect fluoroquinolones [Editorial]. Int. J. Tuberc. Lung Dis. 2009 13 : 1319.
127. Palomino JC. Newer diagnostics for tuberculosis and multi-drug resistant tuberculosis. Curr. Opin. Pulm. Med. 2006 12 : 172 178.
128. Barnard M, Albert H, Coetzee G et al. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am. J. Respir. Crit. Care Med. 2008 177 : 787 792.
129. Evans J, Stead MC, Nicol MP et al. Rapid genotypic assays to identify drug-resistant Mycobacterium tuberculosis in South Africa. J. Antimicrob. Chemother. 2009 63 : 11 16.
130. Nolte FS, Metchock B, McGowan JE et al. Direct detection of Mycobacterium tuberculosis in sputum by polymerase chain reaction and DNA hybridization. J. Clin. Microbiol. 1993 31 : 1777 1782.
131. Lin SYG, Probert W, Lo M et al. Rapid detection of isoniazid and rifampin resistance mutations in Mycobacterium tuberculosis complex from cultures or smear-positive sputa by use of molecular beacons. J. Clin. Microbiol. 2004 42 : 4204 4208.
132. Caviedes L, Lee TS, Gilman RH et al. Rapid, efficient detection and drug susceptibility testing of Mycobacterium tuberculosis in sputum by microscopic observation of broth cultures. J. Clin. Microbiol. 2000 38 : 1203 1208.
133. Hamid Salim A, Aung KJM, Hossain MA et al. Early and rapid microscopy-based diagnosis of true treatment failure and MDR-TB. Int. J. Tuberc. Lung Dis. 2006 10 : 1248 1254.
134. Pai M, Kalantri S, Pascopella L et al. Bacteriophage-based assays for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a meta-analysis. J. Infect. 2005 51 : 175 187.
135. Martin A, Portaels F, Palomino JC. Colorimetric redox-indicator methods for the rapid detection of multidrug resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. J. Antimicrob. Chemother. 2007 59 : 175 183.
136. Martin A, Cubillos-Ruiz A, Von Groll A et al. Nitrate reductase assay for the rapid detection of pyrazinamide resistance in Mycobacterium tuberculosis using nicotinamide. J. Antimicrob. Chemother. 2008 61 : 123 127.
137. Hillemann D, Ruesch-Gerdes S, Richter E. Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J. Clin. Microbiol. 2009 47 : 1767 1772.
138. Global Alliance for TB Drug Development. Handbook of anti-tuberculosis agents. TMC-207. Tuberculosis 2008 88 : 168 169.
139. Veziris N, Ibrahim M, Lounis N et al. A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis. Am. J. Respir. Crit. Care Med. 2009 179 : 75 9.
140. Global Alliance for TB Drug Development. Handbook of anti-tuberculosis agents. PA-824. Tuberculosis 2008 88 : 134 136.
141. Singh R, Manjunatha U, Boshoff HIM et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 2008 322 : 1392 1395.
142. Tasneen R, Tyagi S, Williams K et al. Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis. Antimicrob. Agents Chemother. 2008 52 : 3664 3668.
143. Nuermberger E, Tyagi S, Tasneen R et al. Powerful and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob. Agents Chemother. 2008 52 : 1522 1524.
144. Wilkinson RJ, Lange C. Vitamin D and tuberculosis. New light on a potent biologic therapy? Am. J. Respir. Crit. Care Med. 2009 179 : 740 742.
145. Abbate E, Vescovo M, Natiello M et al. Tuberculosis extensamente resistente (XDR-TB) en Argentina: aspectos destacables, epidemiologicos, bacteriologicos, terapeuticos y evolutivos. Rev. Argent. Med. Respir. 2007 7 : 19 25.